BIO-key Seeks Shareholder Nod for M&K CPAs as New Auditor After Dismissing Bush & Associates
BKYI sits 47% above its 52-week low of $3.1 on light trading volume (0.2× avg).
Summary
BIO-key's definitive proxy for its September 3 annual meeting asks shareholders to ratify newly hired auditor M&K CPAs, following the July 2 dismissal of Bush & Associates. The auditor change adds a governance red flag to an already distressed company facing going concern doubts and recent Nasdaq delisting proceedings.
Key Events · Corporate Governance and Compliance · BKYI
-
Auditor Ratification Vote
Shareholders will vote on ratifying M&K CPAs, PLLC as the independent auditor for fiscal 2026. M&K was engaged on July 2, 2026, the same day Bush & Associates was dismissed.
-
Recent Auditor Dismissal
Bush & Associates was dismissed on July 7, 2026, after serving since April 2024. Its audit reports for 2024 and 2025 included going concern explanatory paragraphs but no adverse opinions or disagreements.
-
Governance Red Flag
The auditor change, occurring amid going concern warnings, a recent Nasdaq delisting notice, and a reverse stock split, raises concerns about financial reporting stability.
-
Annual Meeting Set for September 3
The meeting will also include election of five directors and an advisory say-on-pay vote. The record date is July 15, 2026, with 1,087,360 shares outstanding.
Analysis · BKYI · Technology
Just weeks after dismissing Bush & Associates on July 2, BIO-key is asking shareholders to ratify M&K CPAs as its independent auditor for 2026. The change lands against a backdrop of going concern warnings, a Nasdaq delisting scare, and a recent reverse stock split — turning the ratification vote into a key governance signal. While the proxy also covers routine director elections and say-on-pay, the auditor ratification stands out given the company's fragile financial position and the abrupt dismissal of the prior firm.
At the time of this filing, BKYI was trading at $4.55 on NASDAQ in the Technology sector, with a market capitalization of approximately $4.9M. The 52-week trading range was $3.10 to $19.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.